Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NTC 801

Drug Profile

NTC 801

Alternative Names: BMS-914392; BMS-914392-01; NTC-801; NTC-801F

Latest Information Update: 19 Jan 2016

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nissan Chemical Industries
  • Developer Nissan Chemical Industries; Teijin Pharma
  • Class Antiarrhythmics
  • Mechanism of Action Potassium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Suspended Atrial fibrillation; Atrial flutter

Most Recent Events

  • 04 Jun 2015 Suspended - Phase-II for Atrial fibrillation in Japan (PO) before June 2015
  • 04 Jun 2015 Suspended - Phase-II for Atrial flutter in Japan (PO) before June 2015
  • 10 Mar 2009 Bristol-Myers Squibb enters into a collaboration with Nissan Chemical Industries and Teijin Pharma for development and commercialisation of NTC 801 worldwide, except Japan, for Atrial fibrillation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top